Smarticles aim to deliver

Published: 20-Mar-2007
Ingredients Sustainability Drug Delivery Research & Development Pharmaceutical


US biopharma company ProNAi Therapeutics, which is pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), has entered into a collaboration with German company Novosom to enable successful delivery of DNAi-based cancer therapeutics.

Under the terms of the collaboration, ProNAi will license Novosom's Smarticles liposome technology for use in all human disease targeted by ProNAi's PNT100 drug candidate. The agreement comprises an upfront payment, milestone payments and royalties. ProNAi will also retain an option for four additional DNAi targets.

See more

You may also like

Research & Development

Brainomix receives FDA clearance of e-Lung AI software

Read more
The software allows healthcare professionals to assess the condition of a patient with interstitial lung disease using AI technology

Trending Articles

  1. UPS Healthcare supports Irish pharma with novel Dublin facility The opening of the facility will expand the global connectivity of the Irish pharmaceutical market, which accounts for 50% of all national exports
  2. LIfT BioSciences receives Innovate UK grant to accelerate IMAN cell therapy product development In vivo studies will be conducted to determine the impact of IMAN cell therapies in solid tumour and immunology models developed by the Saeb-Parsy Lab at the University of Cambridge
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  4. BenevolentAI and AstraZeneca collaboration finds novel heart failure target The heart failure target was discovered through an AI platform, with AstraZeneca then experimentally validating its clinical potential
  5. NeuroSense and PhaseV partner to optimise ALS Phase III trial using causal machine learning PhaseV's causal machine learning predicts high probability of success in multiple ALS subgroups for NeuroSense's Phase II trial

Upcoming event

BIO International Convention Digital

3-6 June, 2024 | Convention | San Diego, US See all

You may also like

Research & Development

Brainomix receives FDA clearance of e-Lung AI software

The software allows healthcare professionals to assess the condition of a patient with interstitial lung disease using AI technology
Manufacturing

Sartorius collaborate with NVIDIA to advance manufacturing with AI

The collaboration will aim to enhance research and development, as well as manufacturing protocols using artificial intelligence (AI)
Packaging

TerraCycle launches BlisterBack solution to increase medicine blister pack recycling

The initiative allows the collection and recycling of medicine blister packs, which would otherwise end up in landfill
Research & Development

Closed Loop Medicine & Pharmanovia's OptiZest study for precision hypertension therapeutic commences

The study will investigate the efficacy of at-home, personalised dose management with Zestril for the treatment of hypertension
Research & Development

LIfT BioSciences receives Innovate UK grant to accelerate IMAN cell therapy product development

In vivo studies will be conducted to determine the impact of IMAN cell therapies in solid tumour and immunology models developed by the Saeb-Parsy Lab at the University of Cambridge
Research & Development

Oxford BioDynamics and King’s College London collaborate to develop EpiSwitch biomarkers for rheumatoid arthritis

Prognostic and predictive biomarkers determined by EpiSwitch technology will allow for best prevention of rheumatoid arthritis following the APIPPRA trial
Distribution

UPS Healthcare supports Irish pharma with novel Dublin facility

The opening of the facility will expand the global connectivity of the Irish pharmaceutical market, which accounts for 50% of all national exports
Subscribe now